Lightspring /
22 September 2014Biotechnology

Sareum granted cancer treatment patent

UK-based cancer drug company Sareum has been granted a patent for an invention forming part of its treatment methods.

Sareum said the patent, granted by the European Patent Office, covered compounds linked to its CHK1 (Checkpoint Kinase 1) cancer programme.

CHK1 is used when controlling a cancer cell’s response to DNA damage, which could be a consequence of the cancer itself or intentionally caused by chemotherapy or radiotherapy.

The patent, EP2288601, has already been granted in the US, the Cambridge-based company said.

“This patent is part of a wide IP estate which, if granted in its current form, would provide broad geographical protection for the CHK1 programme,” Sareum said in a statement today, (September 22).

Chief executive, Tim Mitchell added: “The IP that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value”.

The CHK1 cancer programme is a co-development collaboration between the Cancer Research Technology Pioneer Fund, investment company BACIT Ltd and Sareum.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at